 Fulcrum Therapeutics, Inc. FULC, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it is on track for submission of an Investigational New Drug IND application to the U.S. Food and Drug Administration FDA in the second half of 2020 for FTX-6058 following the completion of preclinical safety studies and Good Laboratory Practices GLP toxicology work. Completed preclinical studies illustrate that FTX-6058, a small molecule upregulator of fetal hemoglobin, has the potential to provide distinct advantages over biologics and gene therapies currently being used or developed for the treatment of sickle cell disease, said Owen B. Wallace, Ph.D., Fulcrums chief scientific officer. 